6 Trends Pharma Should Follow: BDO Life Sciences Letter Explains

With President Trump past his 100-day mark, the future of a slew of floated regulatory and legislative changes hangs in the balance, including lowering drug prices and expediting the approval of new drugs and medical devices.

From a regulatory perspective, changing tax laws and accounting rules have forced many U.S. life sciences companies to rethink their tax planning, IP holding structures and financial reporting methodology. From a legislative perspective, U.S. healthcare reform is still under debate, with all eyes on the Affordable Care Act (ACA), the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) and other value-based reimbursement initiatives. At the same time, sophisticated technologies continue to disrupt the industry, leading to medical breakthroughs and improved patient care, while also forcing providers to rethink their traditional business models.

In the Spring 2017 Life Sciences Letter, we delve into these issues and more, highlighting key compliance implications—and areas of opportunity—life sciences companies must consider to ensure their long-term success.

Our latest life sciences newsletter features: Download the full issue here for these articles and more.  

Don’t miss the latest BDO News and insights – subscribe here.